Semaglutide biosimilar(Livzon Group)

司美格鲁肽生物类似药（丽珠集团）

Report date: 2024/06/13 10:32:19

Base Information

Drug NameSemaglutide biosimilar(Livzon Group)
Drug Alias Namesemaglutida索马鲁肽semaglutidum索玛鲁肽司美鲁肽 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesLivzon New North River Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLivzon New North River Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG